News | May 14, 2012

Boston Scientific Introduces ICD, CRT-D Warranties of Up to 10 Years

May 14, 2012 ? Boston Scientific Corp. announced extended warranties of up to 10 years, depending on the model, for its Energen and Incepta implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). The company said the new warranty program is the longest available in the industry and provides physicians, patients and payers across Europe warranties up to five years longer than other currently-marketed cardiac devices. Following are the devices and their warranties. 

- Energen and Incepta VR ICD, 10-year device warranty     
- Energen and Incepta DR ICD, eight-year device warranty     
- Energen and Incepta CRT-D, six-year device warranty 

"Having such a warranty for devices gives physicians assurance about longer battery life and can provide patients with greater peace of mind. This is a major factor to consider when selecting a specific device to implant," said Dr. Oliver Przibille, FESC, CCB, Herzschrittmacher-Centrum, Frankfurt, Germany. 

"From a psychological point of view, an extended warranty has an extremely positive effect on a patient's perception and acceptance of this therapy, because a long warranty means the manufacturer is confident about the longevity of its devices," said Dr. Roberto Verlato, head of cardiology department, Camposampiero Hospital, Italy. 

Boston Scientific's warranty program is based on real-world data from more than 67,000 devices, which include the company's advanced battery technology that offers greater capacity compared to other ICD and CRT-D batteries and includes numerous energy-saving features. 

Currently, 14 million Europeans have heart failure, and this number may rise to 30 million by 2020 as a result of the aging population and the effectiveness of recent treatments to lengthen patients' survival. Heart failure is associated with frequent hospital admissions, which represent the main driver of treatment costs (67-75 percent). On average, heart failure treatment costs amount to 1-2 percent of each country's total healthcare budget in Europe. 

For more information:


Related Content

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init